Matt Abernethy, Chief Financial Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 5,020 shares at $157.20 ($786K) on 2026-09-14, disclosed to the SEC on 2026-09-15.
Scheduled sale ($786k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $156.22 | 2,709 | $423K | 53.8% |
| 2 | $157.20 | 2,311 | $363K | 46.2% |
| Total | $156.67 avg | 5,020 | $786K | 100% |
| Filing → |
| NBIX | SELL | 2025-02-04 | $392K | — | Filing → |
| NBIX | SELL | 2024-08-15 | $2.1M | — | Filing → |
| NBIX | SELL | 2024-07-18 | $135K | — | Filing → |